TGTGInsighttelegram intelligenceLIVE / telegram public index
← GitHub Trends

TGINSIGHT SIMILAR POSTS

Find similar content

Source channel @githubtrending · Post #15601 · Apr 5

#yara#awesome_list#blueteam#blueteam_tools#cti#detection#detection_engineering#dfir#hacktools#incident_response#ioc#iocs#ir#ransomware#redteam#rmm#security#siem#soc#threat_hunting#threat_intelligence You can access comprehensive security detection lists and threat hunting resources that help identify malicious activity across your infrastructure. These curated collections include indicators like suspicious file hashes, domain names, IP addresses, and behavioral patterns organized by threat type—from ransomware and phishing to command-and-control servers and vulnerable drivers. By integrating these lists into your security tools like SIEM platforms and endpoint detection systems, you gain immediate visibility into known threats while learning detection methodologies through guides and YARA rules. This accelerates your ability to hunt for compromises, validate security controls, and stay current with emerging attack techniques without building detection logic from scratch. https://github.com/mthcht/awesome-lists

Results

2 similar posts found

Search: #drugdevelopment

当前筛选 #drugdevelopment清除筛选
Crypto M - Crypto News

@CryptoM · Post #64470 · 04/09/2026, 01:45 AM

🚀 Hong Kong's Innovative Drug Sector Gains Momentum Hong Kong's innovative drug sector is experiencing a surge, with several companies showing significant gains. According to Jin10, Ascletis Pharma (01672.HK) saw an increase of over 3%, while Hansoh Pharmaceutical (03692.HK) rose by more than 2%. Other companies such as WuXi AppTec (02359.HK) and Sihuan Pharmaceutical (00460.HK) also followed suit with upward trends. #HongKong#Pharmaceuticals#Biotech#Innovation#StockMarket#Healthcare#DrugDevelopment

Venture Village Wall 🦄

@venturevillagewall · Post #3642 · 12/21/2024, 10:23 AM

PeproMene Bio Secures $11M Round PeproMene Bio, Inc., a clinical-stage biotech firm based in Irvine, CA, has successfully raised $11 million in funding. The investment round closed on December 18, 2024, focusing on innovative therapies targeting cancers and immune disorders. More info: PeproMene Bio #Biotech#Funding#Cancer#ImmuneDisorders#California#ClinicalStage#Therapies#Investment#Healthcare#Innovation#PeproMeneBio#Pharmaceuticals#MedicalResearch#DrugDevelopment